C-Pep

C-Peptide

Metabolic Panel

What is C-Peptide?

C-peptide (connecting peptide) is a 31-amino-acid peptide that is released into the bloodstream in equimolar amounts with insulin during the processing of proinsulin in pancreatic beta cells. When proinsulin is cleaved in secretory granules, it produces one molecule of insulin and one molecule of C-peptide. Unlike insulin, which is substantially extracted by the liver on first pass (about 50%), C-peptide is cleared primarily by the kidneys at a steady rate, giving it a longer half-life (about 30 minutes versus 5 minutes for insulin) and more stable blood levels. This makes C-peptide a more reliable measure of endogenous insulin production than insulin itself.

C-peptide measurement is clinically essential for classifying diabetes type, monitoring residual beta-cell function, evaluating hypoglycemia, and distinguishing endogenous from exogenous insulin sources. In type 1 diabetes, C-peptide levels are very low or undetectable because autoimmune destruction eliminates beta cells. In type 2 diabetes, C-peptide levels are typically normal or elevated due to insulin resistance driving increased production. In cases of hypoglycemia, C-peptide helps differentiate insulinoma (high C-peptide) from surreptitious insulin injection (low C-peptide with high insulin).

Why It Matters

C-peptide is the definitive test for measuring how much insulin your pancreas is producing. It is critical for distinguishing type 1 from type 2 diabetes—a distinction that determines whether insulin therapy is absolutely necessary or whether oral medications may be effective. In patients with diabetes of uncertain type (especially adults with latent autoimmune diabetes, LADA), C-peptide helps guide treatment decisions. It is also the key test in hypoglycemia workups: a high C-peptide with low blood sugar suggests an insulin-producing tumor or medication effect, while a suppressed C-peptide points toward exogenous insulin as the cause.

Normal Reference Ranges

GroupRangeUnit
Fasting Adults0.8–3.1ng/mL
After glucose stimulation5–12ng/mL
Type 1 diabetes (typical)<0.2ng/mL

Reference ranges may vary by laboratory. Always compare results to the ranges provided by your testing facility.

What High C-Pep Levels Mean

Common Causes

  • Type 2 diabetes (insulin resistance driving overproduction)
  • Insulinoma (insulin-producing pancreatic tumor)
  • Sulfonylurea use (stimulates insulin secretion)
  • Kidney failure (decreased C-peptide clearance)
  • Obesity and metabolic syndrome
  • Cushing syndrome
  • Pancreatic beta-cell hyperplasia

Possible Symptoms

  • Hypoglycemia episodes (if from insulinoma or sulfonylurea)
  • Sweating, tremor, confusion, loss of consciousness (neuroglycopenia)
  • Weight gain
  • Symptoms of underlying insulin resistance (acanthosis nigricans)
  • Often asymptomatic when elevated in type 2 diabetes

What to do: Elevated C-peptide in the setting of type 2 diabetes confirms insulin resistance and preserved beta-cell function—treatment focuses on lifestyle modification, metformin, and insulin sensitizers. If elevated C-peptide is found with hypoglycemia, evaluate for insulinoma (72-hour supervised fast, CT/MRI of pancreas, endoscopic ultrasound) or sulfonylurea ingestion (check sulfonylurea screen). In kidney disease, elevated C-peptide may reflect decreased clearance rather than increased production—interpret in context of eGFR.

What Low C-Pep Levels Mean

Common Causes

  • Type 1 diabetes (autoimmune beta-cell destruction)
  • Latent autoimmune diabetes in adults (LADA)
  • Advanced type 2 diabetes (beta-cell exhaustion)
  • Pancreatectomy (surgical removal of pancreas)
  • Chronic pancreatitis with beta-cell destruction
  • Exogenous insulin administration (suppresses endogenous production)

Possible Symptoms

  • Hyperglycemia and polyuria
  • Polydipsia (excessive thirst)
  • Unexplained weight loss
  • Diabetic ketoacidosis (in type 1)
  • Labile blood glucose levels
  • Need for insulin therapy

What to do: Low C-peptide in a patient with diabetes confirms insulin deficiency and the need for insulin therapy. If type 1 diabetes is suspected, check diabetes autoantibodies (GAD65, IA-2, ZnT8, insulin autoantibodies) for confirmation. In patients diagnosed with type 2 diabetes who have declining C-peptide, screen for LADA with autoantibodies—these patients often need earlier transition to insulin. A C-peptide <0.2 ng/mL indicates near-complete beta-cell loss. Serial C-peptide measurements can track the gradual decline in beta-cell function over time and guide therapy adjustment.

When Is C-Pep Testing Recommended?

  • When classifying diabetes type (type 1 vs. type 2 vs. LADA)
  • When evaluating hypoglycemia of unknown cause
  • When monitoring beta-cell function in diabetes
  • When insulinoma is suspected
  • When differentiating endogenous from exogenous insulin
  • After pancreatic surgery to assess residual function

Frequently Asked Questions

C-peptide is preferred over insulin for several reasons. First, insulin is heavily extracted by the liver (about 50% on first pass), so peripheral insulin levels do not accurately reflect pancreatic secretion—C-peptide is not extracted by the liver and provides a more accurate measure of beta-cell output. Second, exogenous insulin (injected insulin) is detected by insulin assays, making it impossible to determine how much the pancreas is producing in insulin-treated patients—C-peptide is not present in pharmaceutical insulin, so it exclusively reflects endogenous production. Third, C-peptide has a longer half-life (30 vs. 5 minutes), resulting in more stable and reproducible levels. Fourth, different insulin assays have variable cross-reactivity with insulin analogs, making insulin measurement less standardized.
Latent Autoimmune Diabetes in Adults (LADA) is a form of autoimmune diabetes that develops more slowly than classic type 1 diabetes, often being initially misdiagnosed as type 2 diabetes. LADA patients are typically adults (>30 years), are often non-obese, and may initially respond to oral medications but progressively lose beta-cell function over months to years. C-peptide helps identify LADA: these patients have C-peptide levels that are initially in the low-normal range (lower than typical type 2) and progressively decline. Positive diabetes autoantibodies (especially GAD65) plus declining C-peptide confirm LADA. Identifying LADA is important because these patients will eventually require insulin and may benefit from earlier insulin initiation to preserve remaining beta-cell function.
When hypoglycemia occurs (blood glucose <55 mg/dL with symptoms), simultaneous measurement of C-peptide, insulin, and proinsulin during the episode is diagnostic. If insulin is elevated and C-peptide is also elevated, the source is endogenous: either an insulinoma (insulin-producing tumor), nesidioblastosis (beta-cell hyperplasia), or insulin secretagogue use (sulfonylureas). If insulin is elevated but C-peptide is low/suppressed, the source is exogenous—injected insulin, which suppresses endogenous insulin and C-peptide production. If both insulin and C-peptide are suppressed, the hypoglycemia is not insulin-mediated. A sulfonylurea screen should also be checked, as these medications elevate both insulin and C-peptide. This framework is the cornerstone of the 72-hour supervised fast used to diagnose insulinoma.

Related Biomarkers

GLUGlucoseInsulinInsulin

Want your C-Pep levels analyzed?

Upload your lab results for an instant AI-powered breakdown of all your biomarkers.

Upload Lab Results →

Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reference ranges may vary between laboratories. Always consult your healthcare provider for interpretation of your specific test results.

Disclaimer: SymptomGPT is not a medical diagnosis tool and does not provide medical advice. Always consult a qualified healthcare professional. If you are experiencing a medical emergency, call 911 immediately.